Insiders Are Dumping These 5 Healthcare Stocks

3. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Number of Hedge Fund Investors: 55

California-based biopharma company Neurocrine Biosciences, Inc. (NASDAQ:NBIX) ranks third in our list of the healthcare stocks with recent insider selling activity. Ingrid Delaet, the Chief Regulatory Officer at Neurocrine Biosciences, Inc. (NASDAQ:NBIX), on March 21 sold 5,000 shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) at $145.06 per share. Another insider selling transaction was initiated by the Chief Commercial Officer of Neurocrine Biosciences, Inc. (NASDAQ:NBIX), Eric Benevich, on March 14. He sold 69,521 shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) at $139.3 per share. Since then the stock is up 1.4%.

Harding Loevner Global Small Companies Equity Strategy made the following comment about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in its Q3 2023 investor letter:

“By sector, our returns in Health Care were positive but this was more than offset by poor Industrials stocks. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reported positive late-stage clinical study data for its treatment of congenital adrenal hyperplasia, a condition which causes the body to not produce enough cortisol, increasing the probability that the company can address a new estimated $1 billion market opportunity.”